

# Index

## A

- ACE. *See* Angiotensin-converting enzyme (ACE)
- Acute exacerbation of pulmonary sarcoidosis (APES)
  - anti-sarcoidosis treatment, 66
  - clinical course, patients, 66
  - definition, 66
  - diagnostic
    - algorithm, 70–72
    - criteria, 66–67
  - epidemiology/risk factors, 67–69
  - pathogenesis, 69
  - prognosis, 75
  - prospective and retrospective studies, 75
  - risk factors, 75
  - standardized therapeutic regimen, 75
  - treatment, 72–75
- Adalimumab
  - biologic agents, sarcoidosis, 53, 54
  - infliximab, 53, 56
- Advanced pulmonary sarcoidosis.  
*See* End-stage sarcoidosis
- Airway stenosis, 62–63
- Angiotensin-converting enzyme (ACE)
  - and PFT, 142
  - respiratory symptoms, 142
- Antiretroviral therapy (ART), 68
- ART. *See* Antiretroviral therapy (ART)
- Azathioprine
  - MTX treatment, 52
  - pharmacologic therapy, sarcoidosis, 49–51

## B

- BAE. *See* Bronchial arterial embolization (BAE)
- BAL. *See* Bronchoalveolar lavage (BAL)
- Biopsy, sarcoidosis
  - bronchoalveolar lavage fluid (BALF), 6, 7
  - clinical presentations, 5, 6
  - conjunctiva, 8
  - diagnostic approach, 8, 9
  - endobronchial, 6
  - granulomas, 7
  - imaging and scanning, 7–8
  - Kveim test, 8
  - lymphocytosis, 7
  - pulmonary involvement, 6
  - tissue, 5, 6
  - transbronchial needle aspiration, 6
- BNP. *See* Brain natriuretic peptide (BNP)
- BOS. *See* Bronchiolitis obliterans syndrome (BOS)
- Brain natriuretic peptide (BNP)
  - biomarker, cardiac dysfunction, 120
  - blood tests, 119
- Bronchial arterial embolization (BAE), 96, 203
- Bronchiectasis
  - corticosteroids/immunosuppressive agents, 91
  - CT, chest, 91
  - cystic fibrosis, 91
  - description, 90
  - fibrotic sarcoidosis, 90
  - management strategies, 92

- Bronchiolitis obliterans syndrome (BOS)  
 IPF and sarcoidosis, 101  
 lung transplant, 102  
 sarcoidosis, 102
- Bronchoalveolar lavage (BAL), 117
- C**
- Calcium dysregulation, 178–179
- Cardiac magnetic resonance imaging (CMR),  
 163–164
- Cardiac sarcoidosis  
 conduction abnormalities, 160  
 diagnosis, 160–164  
 heart failure, 159–160  
 myocardial involvement, 159  
 pericardial disease, 160  
 treatment, 164–165
- Cavitary lung disease  
 antifungal agents, 96  
 aspergillomas, 95  
*Aspergillus fumigatus*, 94  
 BAE, 96  
 cavernostomies, 95  
 conglomeration, 94  
 CT, chest, 94, 95  
 description, 93  
 diagnosis, 94  
 ectatic bronchi, 93  
 hemoptysis, 95, 96  
 right and left lungs, 94  
 treatment, aspergillomas, 96  
 upper lobe mycetoma, 94
- Chest radiography  
 ACE levels, 142  
 and disease activity, 132  
 HRCT, 141  
 monitoring, 139–140  
 and PFTs (*see* Pulmonary function tests  
 (PFTs))  
 and spirometry, 130  
 stages III and IV, 135
- Chest X-ray  
<sup>18</sup>F-FDG PET, 35  
 pulmonary fibrosis, 31  
 sarcoidosis patients, 21  
 stage I sarcoidosis, 24
- Chronic obstructive pulmonary disease (COPD)  
 chronic lung diseases, 96  
 and IPF, 83
- CMR. *See* Cardiac magnetic resonance  
 imaging (CMR)
- COP. *See* Cryptogenic organizing pneumonia  
 (COP)
- COPD. *See* Chronic obstructive pulmonary  
 disease (COPD)
- Corticosteroids  
 APES, 73  
 chronic sarcoidosis, 75  
 empiric therapy, 72  
 sparing agent, 74–75  
 treatment, 67–68  
 WASOG, 72–73
- Cryptogenic organizing pneumonia  
 (COP), 29
- D**
- Definition, APES, 66
- Diagnosis  
 APES, 66–67, 70  
 cardiac sarcoidosis  
 CMR, 163–164  
 definition, 160–161  
 electrocardiography (ECG)  
 abnormalities, 162  
 endomyocardial biopsy, 161  
 Japanese Ministry of Health and  
 Welfare criteria, 161  
 noninvasive nuclear radiography,  
 162–163
- hepatic sarcoidosis  
 CT imaging, 174–175  
 histopathology, 175–176
- neurosarcoidosis  
 ACE, 157  
 clinical advantage and practicality, 155  
 CSF analysis, 156  
 neural tissue biopsy, 155  
 noncaseating granulomas, 155  
 noninvasive test imaging, 156  
 ocular involvement, 156  
 tissue biopsy, 156
- ocular sarcoidosis, 167–168
- sarcoidosis  
 ACE, 5  
 clinical data collection, 3  
 clinicoradiographic data, 3  
 demographics, 3  
 extrapulmonary involvement, 4  
 multistep process, 2  
 patients, medical history, 4  
 radiographic findings, 4–5  
 splenic sarcoidosis, 177–178
- Differential diagnosis, APES, 70, 72
- Diffusing capacity of the lung for carbon  
 monoxide (DLCO), 89
- Distance saturation product (DSP), 120

DLCO. *See* Diffusing capacity of the lung for carbon monoxide (DLCO)  
 DSP. *See* Distance saturation product (DSP)

## E

End-stage sarcoidosis  
 airway stenosis, 62–63  
 bronchiectasis (*see* Bronchiectasis)  
 cavitory lung disease and mycetomas, 93–96  
 CT, chest, 88  
 description, 80  
 disease activity and medical therapy, 97–98  
 “fibrotic granulomatous”, 81  
 fibrotic pattern, chest radiography, 80–81  
 lung transplantation (*see* Lung transplantation)  
 mortality and prognostic factors, 83–84  
 PFTs, 81  
 and PH, 89–90  
 pulmonary fibrosis (*see* Pulmonary fibrosis)  
 pulmonary function tests, 89  
 renal replacement therapy, 80  
 risk factors, persistent disease, 81–83  
 symptom control, 96–97  
 symptoms and signs, 87–88

Erythema nodosum (EN), 170–171

Etiology, 14

Extrapulmonary sarcoidosis

cardiac sarcoidosis (*see* Cardiac sarcoidosis)  
 dysfunction of calcium metabolism, 150  
 extrapulmonary organs, 149  
 granulomatous disorder, 149  
 hepatic sarcoidosis (*see* Hepatic sarcoidosis)  
 laboratory tests, 150  
 neurosarcoidosis (*see* Neurosarcoidosis)  
 organ involvement, 150  
 patients, biopsy-confirmed sarcoidosis, 150–152

## F

<sup>18</sup>F-FDG-PET. *See* <sup>18</sup>F-Fluorodeoxyglucose-PET (<sup>18</sup>F-FDG-PET)

<sup>18</sup>F-Fluorodeoxyglucose-PET (<sup>18</sup>F-FDG-PET)  
 active pulmonary and extrapulmonary sarcoidosis, 35  
 parenchymal disease activity, 35  
 pulmonary disease activity, 35  
 sarcoidosis activity, 34–35

Fibrocystic sarcoidosis

bronchiectasis, 203  
 bronchiectatic airway clumping, 204

hyperlipidemia, 202  
 mycetomas, 204–206  
 pneumothorax, 206  
 pulmonary function testing, 202  
 resting oxygenation, 204  
 right-sided pleuritic chest pain, 202  
 staging system, 204

Forced vital capacity (FVC)

description, 134  
 and DLco levels, 136  
 mortality, 133  
 performance and reproducibility, 133  
 pulmonary disease, 136

FVC. *See* Forced vital capacity (FVC)

## G

Granulomatous inflammation, 9–11

## H

Hepatic sarcoidosis

cirrhosis, 174  
 clinical symptoms, 173–174  
 diagnosis, 174–176  
 granuloma, 173  
 treatment, 176–177

High resolution computed tomography (HRCT)

classical perilymphatic distribution, 27  
 fibrotic changes, 30  
 fibrotic pulmonary sarcoidosis, 32  
 FVC/DLco levels, 136  
 ground glass attenuation, 29  
 interpretation, 24  
 monitoring, 140–141  
 nodular change, 142  
 nodules distribution, 25  
 pulmonary sarcoidosis, 23, 25

Hilar lymphadenopathy

characteristic distribution, 24  
 chest imaging, 188  
 differential diagnosis, 23  
 interstitial lung diseases, 23  
 intrathoracic manifestation, 22  
 lymph node calcification, 23–24  
 nodal stations, 22  
 pulmonary hypertension, 192  
 pulmonary sarcoidosis at HRCT, 23  
 sarcoidosis and tuberculosis, 24  
 stage I represents, 20  
 unilateral hilar lymphadenopathy, 22  
 whole body positron-emission computed tomography, 193, 194

HLA. *See* Human leukocyte antigen (HLA)

HRCT. *See* High resolution computed tomography (HRCT)  
 Human leukocyte antigen (HLA), 69  
 Hydroxychloroquine  
   chloroquine, 52  
   pharmacologic therapy, sarcoidosis, 49–51

## I

ICAB. *See* Intracavitary instillation of amphotericin B (ICAB)  
 Idiopathic multiorgan granulomatous syndromes, 14  
 Idiopathic pulmonary fibrosis (IPF)  
   and BOS, 101  
   and COPD, 83  
   and DLCO, 89  
   lung transplantation, 99  
 ILD. *See* Interstitial lung disease (ILD)  
 Infliximab  
   and adalimumab, 56  
   anti-TNF antibody, 53  
   biologic agents, sarcoidosis, 53, 54  
   chronic pulmonary sarcoidosis, 53  
   pulmonary sarcoidosis, 53  
 Interstitial lung disease (ILD)  
   pulmonary function test parameter, 120  
   vascular destruction, 115  
 Intracavitary instillation of amphotericin B (ICAB), 203  
 Intrathoracic manifestations, sarcoidosis, 22  
 IPF. *See* Idiopathic pulmonary fibrosis (IPF)

## K

Kveim test, 8

## L

Leflunomide  
   hypertension and peripheral neuropathy, 52  
   MTX treatment, 52  
   pharmacologic therapy, sarcoidosis, 49–51  
 LIP. *See* Lymphocytic interstitial pneumonia (LIP)  
 Lung parenchyma, 204  
 Lung transplantation  
   BOS and mortality, 102  
   candidacy, 100–101  
   disease recurrence, 102–103  
   mortality rate, 103  
   survival rates, 102  
   transplant window, 99–100  
   types, 101

Lymphadenopathy  
   bilateral hilar, 20  
   hilar and mediastinal (*see* Hilar lymphadenopathy)  
 Lymphocytic interstitial pneumonia (LIP), 30

## M

Mean pulmonary artery pressure (mPAP)  
   and FVC, 114  
   PAH targeted therapy, 122  
   and PDE-5, 124  
   PVR and 6MWT distance, 124  
   and RHC, 113  
 Mediastinal lymphadenopathy  
   fibrocystic sarcoidosis, 203  
   invasive ductal carcinoma, 193  
 Methotrexate (MTX)  
   acute pulmonary sarcoidosis, 47  
   folic and folinic acid, 48  
   liver biopsies, 48  
   nausea and leukopenia, 52  
   pharmacologic therapy, sarcoidosis, 48, 49–51  
   steroid-sparing cytotoxic agent, 48  
 6-Min walk test (6MWT)  
   and SpO<sub>2</sub>, 120  
   WHO functional class, 124  
 Monitoring  
   PFTs (*see* Pulmonary function tests (PFTs))  
   pulmonary sarcoidosis (*see* Pulmonary sarcoidosis)  
 Mortality and prognostic factors  
   demographic factors, 84  
   IPF and COPD, 83  
   non-Hispanic blacks and Hispanic whites, 84  
   PH, 84  
   radiographic stage 4, 84  
   sarcoidosis, 84  
 mPAP. *See* Mean pulmonary artery pressure (mPAP)  
 MTX. *See* Methotrexate (MTX)  
 6MWT. *See* 6-Min walk test (6MWT)  
 Mycetomas  
   acute bleeding, 205–206  
   chest CT scan, 202, 203  
   environmental microbes, 204  
   hemoptysis, 205  
   instillation of antifungals, 206  
   lung disease, 205

**N**

Necrotizing sarcoid granulomatosis (NSG), 34

Neurosarcoidosis

- cranial neuropathies, 153, 154
- diagnosis, 155–157
- extraneural sarcoid, 153
- hypothalamic/pituitary involvement, 155
- meningeal involvement, 153, 154
- peripheral neuropathy, 155
- prognosis, 158–159
- seizures, 153
- symptomatic neurologic involvement, 150
- treatment, 157–158

NSG. *See* Necrotizing sarcoid granulomatosis (NSG)

N-terminal fragment-proBNP (NT-proBNP)

- biomarker, 120
- ILD patients, 120

NT-proBNP. *See* N-terminal fragment-proBNP (NT-proBNP)

**O**

Ocular sarcoidosis

- conjunctival and lid involvement, 166, 167
- diagnosis, 167–168
- polymorphism, 165
- prognosis, 169
- treatment, 168–169
- uveitis, 166, 167

**P**

PAH. *See* Pulmonary arterial hypertension (PAH)

Parenchymal involvement

- fibrotic sarcoidosis, 30–31
- galaxy sign, cluster sign and halo sign, 27, 29
- ground glass opacities, 29–30
- interstitial lung disease, 24–25
- large nodules and alveolar sarcoidosis, 27, 28
- mosaic attenuation pattern and airtrapping, 31–32
- nodular and reticulonodular pattern, 25–27
- sarcoidosis, 25

Pathology, sarcoidosis, 8–10

PDE-5. *See* Phosphodiesterase 5 (PDE-5)

Peripheral lymphadenopathy, 179

PET. *See* Positron emission tomography (PET)

PFTs. *See* Pulmonary function tests (PFTs)

PH. *See* Pulmonary hypertension (PH)

Phosphodiesterase 5 (PDE-5), 124

Pleural involvement

- chylothorax, 33
- effusion, 32–33
- pneumothorax, 33

Pneumothorax, 206

Positron emission tomography (PET), 34–35

Prednisone

- acute pulmonary sarcoidosis, patients, 47
- Muers' score, 44
- placebo patients, 47
- toxicity, 47

Pulmonary arterial hypertension (PAH)

- and BAL, 117
- ET-1 concentrations, 117
- idiopathic disease, 114
- inflammatory pathway, 117
- and RESAPH, 122
- and SAPH, 115
- targeted therapy, 122

Pulmonary exacerbation. *See* Acute exacerbation of pulmonary sarcoidosis (APES)

Pulmonary fibrosis

- chest X-ray, 31
- description, 85
- extensive parenchymal abnormalities, 34
- fibrotic scar pattern, 86
- granulomas, 31
- honeycombing and reticular opacities, 86
- hyalinized granuloma, 85
- idiopathic, 31
- IL-4 and IL-13, 86
- infarct-like necrosis, 34
- non-necrotizing granulomas, 35
- pro-fibrotic growth factors and cytokines, 87
- respiratory failure, 85
- sarcoidosis, 85
- surgical lung biopsies, 85
- transcriptome analysis, 86

Pulmonary function tests (PFTs)

- abbreviations, 130
- chest radiography, 140
- and clinical approach, 135
- and DLCO, 89
- monitoring
  - biological control subjects, 133
  - calculations, 133
  - clinical approach, 134, 135
  - description, 133
  - and DLco, 134
  - and FVC values, 134
  - heterogeneity, patterns, 135–136
  - interstitial lung disease, 133
  - IPF and FVC, 133

- Pulmonary function tests (PFTs) (*cont.*)  
 pulmonary function trends, 138  
 spirometric variables and measures, 138  
 and radiological findings, 81  
 restrictive/obstructive patterns, 89
- Pulmonary function trends. *See* Pulmonary function tests (PFTs)
- Pulmonary hypertension (PH)  
 anti-inflammatory and immunomodulating therapies, 122  
 description, 89  
 endothelin pathway, 124  
 mPAP and RHC, 113  
 nitric oxide and phosphodiesterase inhibitors, 124  
 prostacyclin pathway, 125  
 recalcitrant dyspnea, 113  
 and RESAPH, 122  
 and SAPH, 89–90, 113–114  
 sarcoidosis, 118–119  
 treatment studies, SAPH, 122, 123
- Pulmonary sarcoidosis  
 breast capsule biopsy, 193, 195  
 breast reconstruction, 193  
 bronchial hyper-reactivity, 130  
 carbon monoxide diffusion capacity, 195  
 chest radiography and spirometry, 130  
 detection, 143  
 “disease activity”, 141–142  
 environmental exposures, 201  
 evolutionary pressures, 201–202  
 fibrocystic sarcoidosis (*see* Fibrocystic sarcoidosis)  
 frequency, monitoring, 144–145  
 genetics, 200–201  
 giant cell formation, 193, 194  
 granulomatous inflammation, 201  
 inorganic antigen exposures, 198–200  
 lupus erythematosus, 196  
 lymphogranulomatosis benigna, 196  
 mediastinal lymph node biopsy, 193, 194  
 monitoring, chest radiography, 139–140  
 organic antigen exposures, 197–198  
 oxygen desaturation, 144  
 and PFTs (*see* Pulmonary function tests (PFTs))  
 SAPH (*see* Sarcoidosis-associated pulmonary hypertension (SAPH))  
 serial HRCT, 140–141  
 symmetrical skin plaques, 195–196  
 symptomatic change, monitoring, 131–132  
 whole body positron-emission computed tomography, 193, 194
- Pulmonary vascular resistance (PVR)  
 hemodynamic improvement, 125  
 and 6MWT distance, 124  
 and PDE-5, 124
- Pulmonary vasculature, 116
- Pulmonary veno-occlusive disease (PVOD), 116, 122
- PVOD. *See* Pulmonary veno-occlusive disease (PVOD)
- PVR. *See* Pulmonary vascular resistance (PVR)
- R**
- Registry of SAPH patients (RESAPH), 122
- Respiratory system. *See* Pulmonary sarcoidosis
- RHC. *See* Right heart catheterization (RHC)
- Right heart catheterization (RHC)  
 and PH, 121  
 sarcoidosis patients, 113
- Right ventricular systolic pressure (RVSP)  
 tricuspid regurgitation jet, 121  
 and TTE, 121
- Risk factors, APES  
 asymptomatic and diagnosis, 68  
 clinical manifestations, 67  
 corticosteroid treatment, 67  
 exacerbations, 67  
 immunosuppressive therapy, 68  
 interferon- $\alpha$  (INF- $\alpha$ ) therapy, 68  
 intrathoracic sarcoidosis, 69  
 prevalence and incidence, 67  
 relapses, 67, 68  
 sarcoidosis exacerbations, 68
- RVSP. *See* Right ventricular systolic pressure (RVSP)
- S**
- SACE. *See* Serum ACE (SACE)
- SAPH. *See* Sarcoidosis-associated pulmonary hypertension (SAPH)
- Sarcoidosis  
 antigen-presenting cell, 14–15  
 biopsy site selection, 5–9  
 chronic beryllium disease, 14  
 clinical criteria, 11–13  
 clinical manifestations, 20  
 definition, 2  
 diagnostic approach, 2–5  
 extrapulmonary (*see* Extrapulmonary sarcoidosis)

- “general organ screen”, 11
  - granulomatous inflammation, 9–11
  - hepatic, 173–176
  - idiopathic multiorgan granulomatous syndromes, 14
  - ocular, 166–169
  - pathology, 8–9
  - pulmonary function test, 21
  - scadding staging, 20–21
  - skin, 169–173
  - splenic, 177–178
  - “splitter approach”, 14
  - tissue biopsy, 5
  - treatment (*see* Treatment, pulmonary sarcoidosis)
  - Sarcoidosis-associated pulmonary hypertension (SAPH)
    - bronchoscopy, 188
    - chest computed tomography (CT) angiogram, 188–189
    - clinical deterioration, 192
    - clinical presentation and diagnostic testing
      - BNP and NT-proBNP, 119–120
      - DSP, 120
      - measurement, PCWP, 122
      - 6MWT and SpO<sub>2</sub>, 120
      - PH and SAPH, 119
      - retrospective studies, 119
      - screening and work up algorithm, 121
      - TTE and RVSP, 121
    - CT scan, chest, 112, 113
    - disease stages, 112
    - fibrosis, 190–191
    - fibrotic sarcoidosis, 90
    - function testing, 188
    - heart catheterization, 89
    - hypoxemia, 191
    - imaging, chest, 192
    - morbidity and mortality, 112, 113
    - multisystem disorder, 112
    - mycetoma, 104
    - myocardial involvement, 191
    - pathophysiology
      - cytokine derangement, 116–117
      - distal capillary bed, 116
      - extrapulmonary manifestations, 118
      - extrinsic compression, pulmonary vessels, 117–118
      - granulomatous vasculopathy, 116
      - ILD, 115
      - PAH and PH, 115
      - PVOD, 113, 114
      - vasoreactivity, 116
      - WHO and PAH, 114
    - PH (*see* Pulmonary hypertension (PH))
    - pulmonary and ocular involvement, 188
    - pulmonary artery pressure, 190
    - pulmonary vasodilators, 193
    - sarcoid granulomata, 190
    - tools, screening, 192
    - treatment strategy, 192
  - Sarcoidosis of the upper respiratory tract (SURT), 21–22
  - Secondary pulmonary lobule (SPL), 24–25
  - Serum ACE (SACE), 5
  - Skin sarcoidosis
    - classification, 169
    - EN, 170–171
    - ichthyosiform, 172
    - Lupus Pernio, 171
    - macular skin lesions, papules, nodules, plaques, 171–172
    - psoriasis, 172
    - skin involvement, 169
    - treatment, 172–173
  - SPL. *See* Secondary pulmonary lobule (SPL)
  - Splenic sarcoidosis
    - clinical signs and symptoms, 177
    - diagnosis, 177–178
    - splenic involvement, 177
    - treatment, 178
  - Stage 4 sarcoidosis
    - escalation, therapy, 97
    - mortality rate, 84
    - mycetoma, 88
  - SURT. *See* Sarcoidosis of the upper respiratory tract (SURT)
  - Symptomatic change
    - acute/subacute infection, 131
    - “breathlessness”, 131
    - bronchocentric symptoms, 132
    - cardiac/pulmonary vascular limitation, 131
    - disease activity, 132
    - dyspnoea, 132
    - “objective” evaluation, 130
    - pulmonary sarcoidosis, 132
    - weight gain and loss, fitness, 131
- T**
- Transthoracic echocardiogram (TTE), 121, 192
  - Treatment
    - APES
      - algorithm, 73
      - anti-sarcoidosis, 69
      - corticosteroid, 67
      - corticosteroids, 73, 74
      - corticosteroid-sparing agents, 74–75

Treatment (*cont.*)

- methotrexate, 74
- pathophysiology, 73
- tumor necrosis factor alpha (TNF- $\alpha$ ), 69
- WASOG, 72
- cardiac sarcoidosis
  - automated implantable defibrillator, 165
  - corticosteroid therapy, 164
  - nonsteroidal immunomodulators, 164–165
- hepatic sarcoidosis, 176–177
- neurosarcoidosis
  - aseptic meningitis, 157
  - baseline corticosteroid therapy, 158
  - cyclophosphamide, 158
  - facial nerve palsy, 157
  - infliximab, 158
  - steroid-sparing immunomodulator therapy, 158
  - thoracic spine, 157
- ocular sarcoidosis, 168–169
- pulmonary sarcoidosis
  - antimalarial agents, 52–53
  - azathioprine, 52
  - cardiopulmonary exercise testing, 44
  - considerations, 57–58
  - cytotoxic drugs, 42
  - forced vital capacity (FVC), 43
  - glucocorticoids, 46–48
  - HRCT imaging, 44
  - indications, 42, 43
  - leflunomide, 52
  - levels, disease, 44, 45
  - lung function, 58
  - methotrexate, 48–51
  - 6-min walk distance (6MWD), 43
  - Muers' score, 44
  - mycophenolate, 52
  - parameters, 43
  - patients, 44
  - PET activity, 44
  - placebo-controlled trials, 42
  - pulmonary and cutaneous disease, 42
  - QOL, 44
  - require systemic therapy, 42
  - rituximab, 56–57
  - skin lesion, 42
  - steroid-sparing agents, 42
  - studies and level, symptoms, 44, 45
  - TNF (*see* Tumor necrosis factor (TNF))
  - skin sarcoidosis, 172–173
  - splenic sarcoidosis, 178
- TTE. *See* Transthoracic echocardiogram (TTE)
- Tumor necrosis factor (TNF)
  - alpha inhibitors, 53
  - antibody infliximab, 53
  - anti-TNF therapy, chronic sarcoidosis, 53, 55
  - biologic agents, sarcoidosis, 53, 54
  - chronic pulmonary sarcoidosis, 53, 55
  - C reactive protein (CRP), 55
  - cutaneous lesions, 53
  - infliximab and adalimumab, 56
  - median FVC, 53, 56
  - physician assessment, 55

## V

- Video-assisted thoracoscopic surgery (VATS), 206

## W

- World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG), 72